बीटा
ट्रायल रडार AI
क्लिनिकल ट्रायल NCT01365169 के लिए घातक सिर और गर्दन का नवोप्लाज्म, घातक नवोप्लाज्म, Metastatic Malignant Neoplasm in the Neck, गर्भाशय ग्रीवा में मेटास्टेटिक घातक नवोप्लाज्म, अग्न्याशयी एडेनोकार्सिनोमा, अग्न्याशय न्यूरोएंडोक्राइन कार्सिनोमा, पुनरावर्ती कोलोरेक्टल कार्सिनोमा, चरण I कोलोरेक्टल कैंसर AJCC v6 और v7, Stage I Hypopharyngeal Carcinoma AJCC V7, Stage I Major Salivary Gland Cancer AJCC V7, Stage I Nasopharyngeal Carcinoma AJCC V7, Stage I Oral Cavity Cancer AJCC V6 and V7, Stage I Oropharyngeal Carcinoma AJCC V6 and V7, चरण II कोलोरेक्टल कैंसर AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC V6 and V7, Stage II Major Salivary Gland Cancer AJCC V7, Stage II Nasopharyngeal Carcinoma AJCC V7, Stage II Oral Cavity Cancer AJCC V6 and V7, Stage II Oropharyngeal Carcinoma AJCC V6 and V7, Stage IIA Colorectal Cancer AJCC V7, Stage IIB Colorectal Cancer AJCC V7, Stage IIC Colorectal Cancer AJCC V7, चरण III कोलोरेक्टल कैंसर AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC V7, Stage III Laryngeal Cancer AJCC V6 and V7, Stage III Major Salivary Gland Cancer AJCC V7, चरण III नासोफैरिंजियल कार्सिनोमा AJCC v7, Stage III Oral Cavity Cancer AJCC V6 and V7, Stage III Oropharyngeal Carcinoma AJCC V7, चरण IIIA कोलोरेक्टल कैंसर AJCC v7, चरण IIIB कोलोरेक्टल कैंसर AJCC v7, चरण IIIC कोलोरेक्टल कैंसर AJCC v7, चरण IV कोलोरेक्टल कैंसर AJCC v7, चरण IVA कोलोरेक्टल कैंसर AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC V7, Stage IVA Laryngeal Cancer AJCC V7, चरण IVA प्रमुख लार ग्रंथि कैंसर AJCC v7, चरण IVA नासोफैरिंजियल कार्सिनोमा AJCC v7, चरण IVA मौखिक गुहा कैंसर AJCC v6 और v7, Stage IVA Oropharyngeal Carcinoma AJCC V7, चरण IVB कोलोरेक्टल कैंसर AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC V7, Stage IVB Laryngeal Cancer AJCC V7, चरण IVB प्रमुख लार ग्रंथि कैंसर AJCC v7, चरण IVB नासोफैरिंजियल कार्सिनोमा AJCC v7, चरण IVB मौखिक गुहा कैंसर AJCC v6 और v7, Stage IVB Oropharyngeal Carcinoma AJCC V7, Metastatic or Locally Unresectable Solid Tumor वर्तमान में भर्ती जारी है। सभी विवरणों के लिए क्लिनिकल ट्रायल रडार कार्ड दृश्य और AI खोज उपकरण देखें, या यहाँ कुछ भी पूछें।
एक परीक्षण फ़िल्टर मानदंडों से मेल खाता है
कार्ड दृश्य
खोज पर वापस जाएँ

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

भर्ती जारी
चिकित्सा परीक्षण का विवरण मुख्य रूप से अंग्रेजी में उपलब्ध है। हालाँकि, ट्रायल रडार AI मदद कर सकता है! बस 'परीक्षण समझाएं' पर क्लिक करें और अपनी चुनी हुई भाषा में परीक्षण की जानकारी देखें और चर्चा करें।
क्लिनिकल परीक्षण NCT01365169 एक हस्तक्रियात्मक चिकित्सकीय अध्ययन है जो घातक सिर और गर्दन का नवोप्लाज्म, घातक नवोप्लाज्म, Metastatic Malignant Neoplasm in the Neck, गर्भाशय ग्रीवा में मेटास्टेटिक घातक नवोप्लाज्म, अग्न्याशयी एडेनोकार्सिनोमा, अग्न्याशय न्यूरोएंडोक्राइन कार्सिनोमा, पुनरावर्ती कोलोरेक्टल कार्सिनोमा, चरण I कोलोरेक्टल कैंसर AJCC v6 और v7, Stage I Hypopharyngeal Carcinoma AJCC V7, Stage I Major Salivary Gland Cancer AJCC V7, Stage I Nasopharyngeal Carcinoma AJCC V7, Stage I Oral Cavity Cancer AJCC V6 and V7, Stage I Oropharyngeal Carcinoma AJCC V6 and V7, चरण II कोलोरेक्टल कैंसर AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC V6 and V7, Stage II Major Salivary Gland Cancer AJCC V7, Stage II Nasopharyngeal Carcinoma AJCC V7, Stage II Oral Cavity Cancer AJCC V6 and V7, Stage II Oropharyngeal Carcinoma AJCC V6 and V7, Stage IIA Colorectal Cancer AJCC V7, Stage IIB Colorectal Cancer AJCC V7, Stage IIC Colorectal Cancer AJCC V7, चरण III कोलोरेक्टल कैंसर AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC V7, Stage III Laryngeal Cancer AJCC V6 and V7, Stage III Major Salivary Gland Cancer AJCC V7, चरण III नासोफैरिंजियल कार्सिनोमा AJCC v7, Stage III Oral Cavity Cancer AJCC V6 and V7, Stage III Oropharyngeal Carcinoma AJCC V7, चरण IIIA कोलोरेक्टल कैंसर AJCC v7, चरण IIIB कोलोरेक्टल कैंसर AJCC v7, चरण IIIC कोलोरेक्टल कैंसर AJCC v7, चरण IV कोलोरेक्टल कैंसर AJCC v7, चरण IVA कोलोरेक्टल कैंसर AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC V7, Stage IVA Laryngeal Cancer AJCC V7, चरण IVA प्रमुख लार ग्रंथि कैंसर AJCC v7, चरण IVA नासोफैरिंजियल कार्सिनोमा AJCC v7, चरण IVA मौखिक गुहा कैंसर AJCC v6 और v7, Stage IVA Oropharyngeal Carcinoma AJCC V7, चरण IVB कोलोरेक्टल कैंसर AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC V7, Stage IVB Laryngeal Cancer AJCC V7, चरण IVB प्रमुख लार ग्रंथि कैंसर AJCC v7, चरण IVB नासोफैरिंजियल कार्सिनोमा AJCC v7, चरण IVB मौखिक गुहा कैंसर AJCC v6 और v7, Stage IVB Oropharyngeal Carcinoma AJCC V7, Metastatic or Locally Unresectable Solid Tumor से जुड़ा हुआ है। परीक्षण वर्तमान में भर्ती जारी चल रहा है। इसकी शुरुआत 25 मई 2011 को हुई थी, और इसमें कुल 590 प्रतिभागियों के नामांकन की योजना है। एमडी एंडरसन कैंसर सेंटर इस परीक्षण का नेतृत्व कर रहे हैं और इसके 30 जून 2027 तक पूरा होने की उम्मीद है। ClinicalTrials.gov वेबसाइट पर यह जानकारी 3 अगस्त 2025 को अंतिम बार अपडेट की गई थी।
संक्षिप्त सारांश
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.
विस्तृत विवरण
PRIMARY OBJECTIVES:

I. To explore the feasibility and acceptability in diverse samples of cancer patients of wireless collection and transmission of data for transfer into the open-source cyberinfrastructure (CI) called Cyberinfrastructure for Comparative Effectiveness Research (CYCORE).

OUTLINE: Patients are assigned to 1 of 4 arms.

ARM I (COLORECTAL CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a global positioning system (GPS) device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

ARM II (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

ARM III (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.

ARM IV (CANCER SURVIVORS THAT ARE CURRENT/FORMER SMOKERS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a carbon monoxide (CO) monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

PANCREATIC CANCER STUDY (PCS): Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.

Technological Approach to Performance Status (TAPS) Study: Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.

आधिकारिक शीर्षक

"CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial"

चिकित्सीय स्थितियाँ
घातक सिर और गर्दन का नवोप्लाज्मघातक नवोप्लाज्मMetastatic Malignant Neoplasm in the Neckगर्भाशय ग्रीवा में मेटास्टेटिक घातक नवोप्लाज्मअग्न्याशयी एडेनोकार्सिनोमाअग्न्याशय न्यूरोएंडोक्राइन कार्सिनोमापुनरावर्ती कोलोरेक्टल कार्सिनोमाचरण I कोलोरेक्टल कैंसर AJCC v6 और v7Stage I Hypopharyngeal Carcinoma AJCC V7Stage I Major Salivary Gland Cancer AJCC V7Stage I Nasopharyngeal Carcinoma AJCC V7Stage I Oral Cavity Cancer AJCC V6 and V7Stage I Oropharyngeal Carcinoma AJCC V6 and V7चरण II कोलोरेक्टल कैंसर AJCC v7Stage II Hypopharyngeal Carcinoma AJCC V6 and V7Stage II Major Salivary Gland Cancer AJCC V7Stage II Nasopharyngeal Carcinoma AJCC V7Stage II Oral Cavity Cancer AJCC V6 and V7Stage II Oropharyngeal Carcinoma AJCC V6 and V7Stage IIA Colorectal Cancer AJCC V7Stage IIB Colorectal Cancer AJCC V7Stage IIC Colorectal Cancer AJCC V7चरण III कोलोरेक्टल कैंसर AJCC v7Stage III Hypopharyngeal Carcinoma AJCC V7Stage III Laryngeal Cancer AJCC V6 and V7Stage III Major Salivary Gland Cancer AJCC V7चरण III नासोफैरिंजियल कार्सिनोमा AJCC v7Stage III Oral Cavity Cancer AJCC V6 and V7Stage III Oropharyngeal Carcinoma AJCC V7चरण IIIA कोलोरेक्टल कैंसर AJCC v7चरण IIIB कोलोरेक्टल कैंसर AJCC v7चरण IIIC कोलोरेक्टल कैंसर AJCC v7चरण IV कोलोरेक्टल कैंसर AJCC v7चरण IVA कोलोरेक्टल कैंसर AJCC v7Stage IVA Hypopharyngeal Carcinoma AJCC V7Stage IVA Laryngeal Cancer AJCC V7चरण IVA प्रमुख लार ग्रंथि कैंसर AJCC v7चरण IVA नासोफैरिंजियल कार्सिनोमा AJCC v7चरण IVA मौखिक गुहा कैंसर AJCC v6 और v7Stage IVA Oropharyngeal Carcinoma AJCC V7चरण IVB कोलोरेक्टल कैंसर AJCC v7Stage IVB Hypopharyngeal Carcinoma AJCC V7Stage IVB Laryngeal Cancer AJCC V7चरण IVB प्रमुख लार ग्रंथि कैंसर AJCC v7चरण IVB नासोफैरिंजियल कार्सिनोमा AJCC v7चरण IVB मौखिक गुहा कैंसर AJCC v6 और v7Stage IVB Oropharyngeal Carcinoma AJCC V7Metastatic or Locally Unresectable Solid Tumor
अन्य अध्ययन आईडी
NCT नंबर
NCT01365169
अध्ययन प्रारंभ तिथि (वास्तविक)
2011-05-25
अंतिम अद्यतन प्रकाशित
2025-08-03
अध्ययन की समाप्ति तिथि (अनुमानित)
2027-06-30
नामांकन (अनुमानित)
590
अध्ययन प्रकार
हस्तक्रियात्मक
चरण
निर्दिष्ट नहीं
स्थिति
भर्ती जारी
प्राथमिक उद्देश्य
स्वास्थ्य सेवा अनुसंधान
डिज़ाइन आवंटन
गैर-यादृच्छिक
हस्तक्षेप मॉडल
समानांतर
अंधकरण
कोई नहीं (खुलें लेबल)
समूह/हस्तक्षेप
प्रतिभागी समूह/हाथहस्तक्षेप/इलाज
प्रयोगात्मकArm I (colorectal cancer patients)
(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
Health Telemonitoring
Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
प्रश्नावली प्रशासन
Ancillary studies
प्रयोगात्मकArm II (head and neck cancer patients)
(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
Health Telemonitoring
Use accelerometers, blood pressure monitor, weight scale, and smart phone
प्रश्नावली प्रशासन
Ancillary studies
प्रयोगात्मकArm III (head and neck cancer patients)
(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
Health Telemonitoring
Use smart phone
प्रश्नावली प्रशासन
Ancillary studies
प्रयोगात्मकArm IV (cancer survivors that are current/former smokers)
(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
Health Telemonitoring
Use CO monitor and smart phone
प्रश्नावली प्रशासन
Ancillary studies
प्रयोगात्मकPCS (pancreatic surgery patients)
Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
व्यायाम हस्तक्षेप
Participate in walking and/or strengthening program
Health Telemonitoring
Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
जीवन की गुणवत्ता का मूल्यांकन
Ancillary studies
प्रश्नावली प्रशासन
Ancillary studies
प्रयोगात्मकTAPS (Technological Approach to Performance Status)
Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.
Health Telemonitoring
Use Fitbit and Actigraph
प्राथमिक परिणाम माप
परिणाम मापमाप विवरणसमय सीमा
Study completion (defined as completing the final assessment)
Up to 7 months after baseline
Physical Activity (PA) Assessment
PA will be measured by two different devices, (1) a consumer-grade wrist-worn device that collects continuous PA data (Fitbit), and (2) a research-grade, hip-worn accelerometer (Actigraph)
Up to 7 days
ECOG Performance Status
Eastern Cooperation Oncology Group (ECOG) is a 6-point performance status scale used to assess performance using PA as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record.
Up to 2 weeks
द्वितीयक परिणाम माप
परिणाम मापमाप विवरणसमय सीमा
Correlation between PA data from the Actigraph and Fitbit
Association between PA measured using a Fitbit and PA measured using Actigraph
Up to 7 days
Correlation between patients' ECOG performance status scores and PA data
Association between performance status (PS) assesses by the patient's medical oncologist, and PA data
Up to 7 days
Correlation between PA data and Overall Survivor (OS)
Association between Physical Activity (PA) data and the Overall Survivor (OS) rate
Up to 7 days
Accrual of Diverse Sample of Cancer-Patients
Up to 2 weeks
Retention of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.
Up to 2 weeks
Acceptability of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.
Up to 2 weeks
Participants ability to activate, set-up, and use the home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).
Up to 2 weeks
Adherence to procedures for home-based health monitor devices activation (e.g. Fitbit, Actigraph, CO monitor, weight scales) self-monitoring (e.g. PA, weight), and self-reported data capture by the devices.
Up to 2 weeks
Successful upload of data from the home-based health monitor devices to the Cyberinfrastructure for Comparative effectiveness Research (CYCORE) for future analysis.
Up to 2 weeks
CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).
Up to 2 weeks
पात्रता मानदंड

अध्ययन के लिए पात्र आयु
वयस्क, वृद्ध वयस्क
अध्ययन के लिए न्यूनतम आयु
18 Years
अध्ययन के लिए पात्र लिंग
सभी
  • Diagnosis of any stage I - IV colorectal cancer or recurrent colorectal cancer (Arm 1)
  • Able to speak, read, and write in English (Pre-pilot phase, Arms 1-4)
  • Able to provide informed consent (Pre-pilot phase, Arms 1-4, PCS study)
  • Lives in the Houston area (Harris county or a contiguous county) (Pre-pilot phase)
  • Eastern Cooperative Oncology Group (ECOG) status of 0 - 2, or self-reports being up and about more than 50% of waking hours and able to provide self-care (Arm 1)
  • Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs) (Arms 2 and 3)
  • History of any cancer, other than non-melanoma skin cancer (Arm 4)
  • Admitted to being a current smoker or recent quitter upon admission to MD Anderson Cancer Center (MDACC) (Arm 4)
  • Has a valid home address and functioning home telephone number (Arm 4)
  • Lives in the Houston or surrounding area, or resides in this same area during the time period that coincides with this study (Arms 1-4)
  • Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)
  • Fluent in English (PCS study)
  • Must have telephone access and agree to engage with research personnel using telephone (PCS study)
  • Diagnosis of a metastatic or locally unresectable solid tumor (TAPS study)
  • Fluent in English (TAPS study)
  • Age 18 years or older (TAPS study)
  • ECOG performance status score between 0-3 (TAPS study)

  • Major surgery in the past 8 weeks (Arms 1 and 4)
  • Self-reports hypertension that is not being monitored by a physician and is not being managed with either medication, observation, or lifestyle change (Pre-pilot phase, Arms 1-3)
  • Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)
  • Orthopedic, neurologic, or musculoskeletal disability that would interfere with the functional task of standing on a weight scale (Pre-pilot phase, Arm 2)
  • Not currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms 2 and 3)
  • Zubrod performance status > 2, or self-reports either not being up and about more than 50% of waking hours or unable to provide self-care (Arms 2 and 3)
  • Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)
  • History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)
  • Active substance use disorder (diagnosed or strongly suspected) (Arm 4)
  • Currently enrolled in protocol 2014-0712 (PCS study)
  • No home access to internet (PCS study)
  • No home WiFi connection (PCS study)
  • During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)
  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV) (PCS study)
  • Recent fracture or acute musculoskeletal injury that precludes the ability to fully bear weight on all 4 limbs in order to participate in an exercise intervention (PCS study)
  • Poorly-controlled pain with a self-reported pain score of 7/10 at the time of enrollment (PCS study)
  • Myopathic or rheumatologic disease that impacts physical function (PCS study)
  • Has a pacemaker or other internal medical device, or reports being pregnant (PCS study)
  • Currently enrolled in protocol 2017-0198 (PCS study)
  • Demonstration of overt cognitive difficulty as demonstrated by not being clearly oriented to time or person or place (TAPS study)
M.D. Anderson Cancer Center logoएमडी एंडरसन कैंसर सेंटर1128 सक्रिय क्लिनिकल ट्रायल्स खोजे जाने के लिए
National Cancer Institute (NCI) logoराष्ट्रीय कैंसर संस्थान, अमेरिका3028 सक्रिय क्लिनिकल ट्रायल्स खोजे जाने के लिए
अध्ययन केंद्रीय संपर्क
संपर्क: Susan Peterson, 713-792-8267, [email protected]
1 1 देशों में अध्ययन स्थल

Texas

M D Anderson Cancer Center, Houston, Texas, 77030, United States
Susan K. Peterson, संपर्क, 713-792-8267
Susan K. Peterson, मुख्य अन्वेषक
भर्ती जारी